Nasdaq · Biological Products, (No Diagnostic Substances)
Two standard screens, computed from the XBRL in FY2026 against FY2025. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2021 | $931.0M | $140.4M | $307.9M | 68.0% | 40,483,000 |
| FY2022 | $1.1B | $272.1M | $280.4M | 68.4% | 41,029,000 |
| FY2023 | $1.1B | $285.3M | $216.1M | 67.7% | 161,855,000 |
| FY2024 | $1.2B | $168.1M | $236.1M | 66.4% | 160,774,000 |
| FY2025 | $1.2B | $73.4M | $256.6M | 64.8% | 159,717,000 |
| FY2026 | $1.2B | $181.9M | $263.2M | 65.8% | 157,009,000 |
13 institutions tracked — 6 added, 6 reduced, 1 opened a new position.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 10,305 | −5,109,880 | $728,049 |
| FMR LLC | Active fund | 12,794,784 | +4,894,856 | $904.0M |
| BlackRock Finance, Inc. | Index | 14,987,870 | −2,758,107 | $1.1B |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 226,000 | −2,221,331 | $16.0M |
| MORGAN STANLEY | Active fund | 6,374,717 | −2,158,156 | $450.4M |
| CITADEL ADVISORS LLC | Hedge fund | 1,050,118 | +875,916 | $74.2M |
| JPMORGAN CHASE & CO | Active fund | 1,862,805 | +837,700 | $132.6M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 5,351,464 | +239,044 | $377.5M |
| Capital World Investors | Active fund | 536,962 | +227,199 | $37.9M |
| BANK OF AMERICA CORP /DE/ | Active fund | 955,237 | −158,336 | $67.5M |
| VANGUARD GROUP INC | Index | 17,810,878 | −121,495 | $1.0B |
| STATE STREET CORP | Index | 5,980,370 | +111,974 | $422.5M |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register. These filings span 2024-Q2–2026-Q2 rather than a single quarter, because filers report on their own schedules.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
BIO-TECHNE Corp files under SIC 2836 — all 11 biological products, (no diagnostic substances) companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
